| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that the American Society of Hematology (ASH) Annual Meeting and Exposition 2023 will feature a broad range of content covering OGM's utility for research in areas including myeloid cancer, hematological malignancy, leukemia and blood disorders.
ASH's Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease. The ASH conference will be held December 9-12, 2023, in San Diego, California and online.
Dr. Enze Liu from Indiana University Medical Center will present findings from a research study utilizing OGM to detect complex SVs in plasma cells that may be associated with disease progression in multiple myeloma (MM) as part of a session titled "Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States." The presentation will take place Sunday, December 10, 2023, at 5:30 pm PT at the Manchester Grand Hyatt Harbor Ballroom.
13 posters featuring results from OGM applications in cytogenetic research will be presented at the conference. Unless otherwise noted below, posters will be available to view at the Manchester Grand Hyatt Harbor Ballroom. Posters displayed at the conference may also be viewed here; online only posters may be viewed here.
Scientific presentations and poster sessions from Bionano and collaborators include:
| Poster Number | Title | Author | Presented |
| 1414 | Partner Gene Associated Trinary Fusion and Orchestration of Multiple Molecular Events in Acute Promyelocytic Leukemia with Variant Rara Fusion Genes | Chen J. | December 9, 2023 5:30-7:30 PM PT |
| 1610 | Deciphering the Structural Variants in B Cell Acute Lymphoblastic Leukemia by Optical Genome Mapping | Liu M. | December 9, 2023 5:30-7:30 PM PT |
| 2834 | Optical Genome Mapping for Genome-Wide Structural Variation Analysis in Hematologic Malignancies: A Prospective Study Demonstrates Additional Findings Compared to Standard-of-Care (SOC) Cytogenomic Methods | Wicks S. | Halls G-H, San Diego Convention Center December 10, 2023 6:00-8:00 PM PT |
| 4116 | Multiomic Characterization of Myelodysplastic Neoplasms (MDS) with Micromegakaryocytes Highlights the Role of EZH2-RUNX1 Deregulation in Disease Hysiopathology and Response to Targeted Therapies Author Links Open Overlay Panel | Fernandez-Serrano M. | December 11, 2023 6:00-8:00 PM PT |
| 4303 | Optical Genomic Mapping Provides Unique Findings in Various Types of Myeloid Neoplasms | Quesada A. | December 11, 2023 6:00-8:00 PM PT |
| 4612 | Comprehensive Characterization of Evolution of Genomic Complexity by Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure | Kanagal-Shamanna R. | December 11, 2023 6:00-8:00 PM PT |
| 5024 | Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine | Díaz-González Á. | December 11, 2023 6:00-8:00 PM PT |
| 5038 | Optical Genome Mapping Allows Detection and Characterization of Cytogenetically Cryptic Oncogenic Fusions in Pediatric Acute Myeloid Leukemia | Raca G. | December 11, 2023 6:00-8:00 PM PT |
| 5039 | Assessment of Optical Genome Mapping for Front-Line Diagnostic Evaluation of Acute Leukemia: A Canadian Single-Center Evaluation of Added Yield in 69 Informative Cases | McGinnis E. | December 11, 2023 6:00-8:00 PM PT |
| Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms | Bris Y. | Online publication | |
| Platinum Talen-Mediated Knock-in of Single-Stranded DNA Templates Facilitates Manufacturing of Clinical-Scale Non-Virally Gene-Edited T Cells from Peripheral Blood | Toishigawa K. | Online publication | |
| Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study | Kaltenbach S. | Online publication | |
| Deciphering the Structural Variants in Acute Myeloid Leukemia and Myelodysplastic Neoplasms by Optical Genome Mapping | Liu M. | Online publication |
| Session | Title | Presenter/s | Presented |
| Platform Presentation | Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma | Liu E. | Harbor Ballroom, Manchester Grand Hyatt December 10, 2023 5:30 PM PT |
"The broad range of presentations on the use of OGM for hematological malignancy research at ASH this year illustrate the importance of OGM in an area of medical research that can really improve patient care in the long run. The ASH conference brings together thousands of clinicians, scientists and industry members working to conquer blood diseases, and we are pleased that OGM and its role in these research areas will be so well-represented at the meeting," stated Erik Holmlin, PhD, president and chief executive officer of Bionano.
More details on the conference can be found here.
Posted In: BNGO
